452 research outputs found
Bibliographie : Octavia römische Geschichte. Zugabe des ersten Theils, [vol. 2] (Nürnberg: J. Hoffmann, 1678)
No full textZweiter Band der ersten Fassung der "Römischen Octavia". Cf. zur vollständigen Publikationsgeschichte: Octavia römische Geschichte, [vol. 1] (Nürnberg: J. Hoffmann, 1677). Enthält mehrere teils wahrscheinlich, teils sicher autorfremde Gedichte. Zwei davon stammen von Christian Hofmann von Hofmannswaldau (vgl. HKA I, pp. CLXXIVf., Anm. 195). Von der "Geschichte der Flavia Domitilla und der Cönis", pp. 920-1015, existiert eine Übersetzung einer unbekannten französischen Hofdame ins Französische, datiert auf den 9. März 1714 (23: Cod.Guelf. 196.1 Extravag.)
MicroWeaR
No full textMicroWeaR is a package to examine and score microwear scars in a semi-automatic way
</p
Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study
No full textIntroduction: Bimekizumab and brodalumab are characterized by a different mechanism of action if compared to the other anti-interleukin (IL)-17s which target IL-17A. Indeed, brodalumab acts on IL-17RA whereas bimekizumab acts on IL-17A, IL-17F, and IL-17AF cytokines. Currently, despite real-life data on the efficacy and safety of bimekizumab and brodalumab have been reported, data comparing these two drugs are absent. However, these data are mandatory to evaluate whether a different target of the same IL can be correlated with a different profile in terms of effectiveness and safety. Moreover, it should be underlined that bimekizumab and brodalumab stood out as the psoriasis treatments with the fastest onset of action, delivering quicker therapeutic responses compared to other drugs acting on IL-17. Methods: A monocentric retrospective study was carried out enrolling patients affected by moderate to severe psoriasis undergoing treatment with brodalumab or bimekizumab. At baseline, clinical demographic details were collected. Clinical improvement [Psoriasis Area Severity Index (PASI), body surface area (BSA)] was collected at weeks 4, 16, and 36. Safety data were analyzed at the same timepoints. Results: A total of 125 patients were enrolled in the study [bimekizumab: 53 (42.40%); brodalumab: 72 (57.6%)]. Psoriasis severity at baseline was similar between the two cohorts. Both PASI and BSA significantly reduced at each follow-up for both treatment cohorts. The bimekizumab group reached a higher percentage of PASI90/PASI100 response at each timepoint as compared to the brodalumab cohort. In particular, the percentage of PASI100 response was significantly higher in the bimekizumab group as compared to the brodalumab cohort at week 4 (41.5% vs 23.6%, p < 0.05) and at week 16 (67.9% vs 48.6%). Discontinuation for ineffectiveness was higher in the brodalumab cohort (8.3%) as compared to the bimekizumab group (3.8%), without statistical significance. As regards safety, two cases of eczematous reactions (bimekizumab: 2, brodalumab: 0), and five cases of candidiasis (bimekizumab: 4, brodalumab: 1) were collected. Overall, 3 (5.7%) and 1 (1.4%) patients discontinued bimekizumab and brodalumab because of adverse events, respectively. Conclusion: Our study confirmed the efficacy and safety of both bimekizumab and brodalumab, up to 36 weeks of treatment. Although both drugs showed a significant improvement of the investigated scores from week 4, some differences in terms of PASI90 and PASI100 responses (higher for bimekizumab at each follow-up, with only PASI100 response significantly higher at week 4 and 16) were registered. No statistical significance was found for safety data and treatment failure
An update on the current and emerging pharmacotherapies for basal cell carcinomas
No full textIntroduction: Despite surgical approach is still the mainstay for basal cell carcinoma (BCC) management, several issues may limit the use of this technique, leading to the need for new treatments to offer patients a personalized approach. Areas covered: A comprehensive review of the available and emerging pharmacologic strategies for BCC management, including mechanisms of action, and potential adverse effects, has been performed to provide with an up-to-date manuscript on the current treatment scenario of BCC. Globally, targeting the Sonic-Hedgehog pathway is one of the main mechanisms of action of currently investigated drugs. Other alternatives are based on the concept of an enhancement of the immune response such as immune checkpoint inhibitors, or intra-tumor treatments. Expert opinion: Although low-risk BCCs are often treated with destructive methods or topical treatments, surgery is the mainstay of treatment for the majority of BCCs. However, several factors may limit the use of surgery in BCC management. Recently, major knowledge on BCCs pathogenesis has led to the development of effective and selective drugs. In our opinion, soon many drugs will be licensed, allowing clinicians to offer patients with BCC the right treatment at the right moment. Certainly, further studies are needed
Dupilumab for the treatment of adult atopic dermatitis in special populations
No full textBackground Special populations (SPs) involve people who require additional consideration in clinical research. Effectiveness of treatment or occurrence of side effects may be different in SPs with respect to not-SPs. Objectives To retrospectively compare the effectiveness and safety of dupilumab in AD treatment of SPs versus not-SPs. Methods A 52-weeks retrospective study was performed enrolling patients with a diagnosis of moderate-to-severe AD undergoing treatment with dupilumab at labeled dosage. Patients were divided in Group A (SPs patients) and Group B (not-SPs patients). Disease severity was assessed using Eczema Area Severity Index (EASI), Pruritus–Numerical Rating Scale (P-NRS), and Dermatology Life Quality Index (DLQI) score at baseline and after 4 weeks (W4), W16, W24, and W52. Results A total of 263 patients were enrolled and divided in Group A (25) and Group B (238). SPs included history of cancer, severe kidney failure, viral hepatitis, neurological diseases, acquired immunodeficiency syndrome, and transplanted patients. A statistically significant reduction of EASI, DLQI, and P-NRS was assessed in both groups at each follow-up visit (p < .0001), without significant differences between the groups. No differences were recorded for safety. Conclusions There are not significant differences between SPs and not-SPs as regards effectiveness and safety of dupilumab in AD management
Stories from the Lapidarium: legio IIII Flavia Felix in Dalmatia
No full textAutor raspravlja o ulomku monumentalne nadgrobne stele neraščlanjenog trupa koja se čuva u lapidariju Arheološkog muzeja Zadar. Stela se ne odlikuje nikakvim posebnostima, a čak joj ni natpis nije potpuno očuvan, no jedan detalj s natpisa otkriva zanimljivu činjenicu koja stvara čvrste temelje za zaključak da je legio IIII Flavia Felix zapravo rekonstituirana legio IIII Macedonica, koja nakon osnivanja zauzima ispražnjeni garnizon na rijeci Krki. Nadalje se raspravlja o dosadašnjim spoznajama o osnutku legije IIII Flavia Felix te njezinu boravku u Dalmaciji, s pregledom do sada poznatih natpisa njezinih pripadnika s dalmatinskog tla.The author discusses the fragment of a single-section funerary stele kept in the Lapidarium of the Archaeological Museum Zadar. Although it does not contain any special features – even its inscription is not fully preserved – a detail of the inscription reveals an interesting fact that can be seen as solid evidence that legio IIII Flavia Felix was actually a reconstituted legio IIII Macedonica that had occupied the vacated encampment on the River Krka. The known facts about the founding of IIII Flavia Felix Legion and its deployment in Dalmatia are also discussed. An overview of the inscriptions containing the legion’s members from Dalmatian soil is also provided
Do-It-Yourself Opinion-Poll Sampling Experiments
No full textThis article, created by Flavia R. Jolliffee of Brunel University, describes a sampling experiments based on opinion-poll type data as an alternative to coin-tossing experiments for social science students. Jolliffe includes interesting data sets within this basic lesson plan. It seems that the author is attempting to provide a more riveting experience for students, at least in comparison to a coin-tossing example. The author provides references for those looking for further information on this topic
Il Boccaccio di Baldassar Castiglione: la duplice immagine del Certaldese nelle pagine del "Cortegiano"
No full textGiovanni Boccaccio is quoted several times in Castiglione’s "Cortegiano", but all these mentions are inserted in two specific contexts: on the one hand, the debate on literary language, developed in the letter of dedication to don Michel De Silva and in the first book; on the other hand, the definition of the joke in book II. Starting from these premises, this essay analyses the meanings of Boccaccio’s presence in the "Cortegiano". It shows that Castiglione’s treatise provides two different and concurrent representations of the author of the "Decameron": a positive one, connected to the ‘questione della lingua’, that offers Boccaccio as a promoter of the usage (‘uso’); a critical one, deriving from the theory of the ‘facezia’, that makes Boccaccio a challenging and challenged model
- …
